Long‐Term Selenium‐Yeast Supplementation Does Not Affect Bone Turnover Markers: A Randomized Placebo‐Controlled Trial

ABSTRACT Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long‐term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of bone and mineral research 2022-11, Vol.37 (11), p.2165-2173
Main Authors: Perri, Giorgia, Hill, Tom R, Mathers, John C, Walsh, Jennifer S, Gossiel, Fatma, Winther, Kristian, Frölich, Jacob, Folkestad, Lars, Cold, Søren, Eastell, Richard
Format: Article
Language:English
Subjects:
Aged
Alkaline Phosphatase
BIOCHEMICAL MARKERS OF BONE TURNOVER
Biomarkers
Body mass index
Bone Remodeling
Bone turnover
Clinical Trial
Collagen (type I)
Dietary Supplements
Epidemiology
Female
GENERAL POPULATION STUDIES
Humans
Male
Mass spectroscopy
Medicin och hälsovetenskap
Middle Aged
NUTRITION
Osteocalcin
Placebos
Plasma
Procollagen
Saccharomyces cerevisiae
Selenium
Selenium - pharmacology
Supplements
Yeast
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Higher selenium status has been associated with lower bone turnover markers (BTM) in epidemiological studies. However, the long‐term impact of selenium supplementation on BTMs has not been studied. We investigated the effects of selenium supplementation on BTMs including osteocalcin (OC), procollagen type I N‐terminal propeptide (PINP), collagen type I cross‐linked C‐telopeptide (CTX), and bone alkaline phosphatase (BALP) in the short (6 months) and long term (5 years). A total of 481 Danish men and women (60–74 years) were randomized to receive placebo‐yeast versus 100, 200, or 300 μg selenium as selenium‐enriched yeast daily for 5 years. Plasma selenium concentration was measured using inductively coupled plasma mass spectrometry, and BTMs were measured in nonfasted samples at baseline, 6 months, and 5 years. Data were analyzed by ANCOVA to investigate the shape of the dose‐response relationships. Covariates included age, body mass index, baseline selenium status, baseline BTM, smoking, alcohol, supplement use, and medication. Plasma selenium concentration (mean 86.5 μg/d at baseline) increased significantly with increasing selenium supplementation to 152.6, 209.1, and 253.7 μg/L after 6 months and remained elevated at 5 years (158.4, 222.4, and 275.9 μg/L for 100, 200, and 300 μg supplemental selenium/d, respectively (p 
ISSN:0884-0431
1523-4681
1523-4681
DOI:10.1002/jbmr.4703